True. Appears to be very attractively valued when one looks at sum of parts (three biz) valuations
Syngene – Listed
Generic – Look at Concord Biotech
These two itself should justify current valuations. Biosimilars seems to be free.
| Subscribe To Our Free Newsletter |
